8-K: Outset Medical Appoints New CFO, Reaffirms 2025 Financial Guidance, and Approves Key Shareholder Proposals

Outset Medical, Inc. announced the appointment of Renee Gaeta as its new Chief Financial Officer, effective June 3, 2025, while also reiterating its 2025 financial guidance and detailing the outcomes of its Annual Meeting of Stockholders.

Summary

• Outset Medical, Inc. has appointed Renee Gaeta as its new Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective June 3, 2025.
• Ms. Gaeta will receive an annual base salary of $500,000, a target annual bonus of 50% of her base salary, a restricted stock unit (RSU) award valued at $2,480,000, and a performance-based restricted stock unit (PSU) award valued at $620,000.
• The PSU award vesting is tied to a financial metric (70%) over a three-year period ending 2027 and relative total stockholder return (30%) against a medical device index over the same period.
• Ms. Gaeta succeeds Nabeel Ahmed, who is departing to pursue other opportunities and will receive severance benefits including nine months of base salary and COBRA premiums.
• The company reiterated its 2025 financial guidance, expecting revenue between $115 million and $125 million and non-GAAP gross margin in the high-30% range.
• At the Annual Meeting of Stockholders held on June 2, 2025, D. Keith Grossman and Patrick T. Hackett were elected as Class II Directors.
• Stockholders approved the advisory vote on named executive officer compensation.
• An amendment to the 2020 Equity Incentive Plan was approved, increasing shares available for issuance by 1,950,000.
• An amendment to the Employee Stock Purchase Plan was approved, increasing shares available for issuance by 255,000.
• KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the appointment of a highly experienced CFO, the reiteration of financial guidance which suggests stability, and the successful approval of all shareholder proposals, indicating strong corporate governance and investor confidence.

Positives

• Appointment of Renee Gaeta as CFO brings extensive experience from publicly traded medical device growth companies, including Shockwave Medical and Establishment Labs, and board roles.
• The company reiterated its 2025 financial guidance, indicating stability and confidence in achieving expected revenue of $115 million to $125 million and non-GAAP gross margin in the high-30% range.
• Shareholders approved key proposals, including the election of directors, executive compensation, and amendments to equity incentive plans, demonstrating strong corporate governance and alignment.
• The increase in shares for the 2020 Equity Incentive Plan and Employee Stock Purchase Plan can help attract and retain talent.

Negatives

• The departure of Nabeel Ahmed as CFO, although stated as for 'other opportunities,' represents a change in key financial leadership.

Risks

• The document notes that forward-looking statements are subject to risks and uncertainties, and factors that could cause actual results to differ materially can be found in the company's SEC filings, including its most recent annual and quarterly reports. No new specific risks were detailed in this filing.

Future Outlook

Outset Medical reiterated its 2025 financial guidance, expecting revenue of $115 million to $125 million and non-GAAP gross margin in the high-30% range. The company aims to drive its next phase of growth and achieve near-term profitability, with the new CFO looking forward to helping achieve these growth and profitability goals.

Management Comments

• "Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companies as both a CFO and board member. She is the ideal fit for Outset as we drive our next phase of growth and our goal to achieve near-term profitability. I want to thank Nabeel for his contributions to Outset and wish him well in his future endeavors." Leslie Trigg, Chair and CEO
• "Outset is transforming dialysis care, and I am honored to join the company as its next CFO. Tablo offers clear and compelling clinical, financial and operational value to acute, post-acute and home dialysis providers. I look forward to playing an important role in helping drive Outset to achieve its growth and profitability goals." Renee Gaeta, Chief Financial Officer

Industry Context

Outset Medical operates in the medical technology sector, specifically pioneering technology to reduce the cost and complexity of dialysis with its Tablo Hemodialysis System. The appointment of Renee Gaeta, with her background at other medical device companies like Shockwave Medical (recently acquired by Johnson & Johnson) and Establishment Labs, reflects a strategic move to leverage experienced leadership from a dynamic and consolidating industry. Her prior board roles at Candel Therapeutics and SeaSpine Holdings (acquired by Orthofix Medical) further underscore her experience within the broader healthcare and medical technology landscape.

Comparison to Industry Standards

• The PSU award for the new CFO is based in part on the company's relative total stockholder return compared to companies in a 'pre-determined index of medical device companies,' indicating a benchmark against industry peers, though specific companies or performance metrics for comparison are not detailed in this document.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Impacted by the election of directors, approval of executive compensation, and the increase in shares available for equity plans (potential future dilution). The reiterated financial guidance provides clarity on expected performance.
• **Employees:** Directly impacted by the new CFO appointment and the approval of increased shares for the equity incentive and employee stock purchase plans, which can enhance compensation and ownership opportunities.
• **Management:** The executive team gains a new CFO with significant industry experience, potentially strengthening financial leadership and strategic execution.
• **Customers/Providers:** The company's continued focus on growth and profitability, supported by strong financial leadership, aims to enhance the value proposition of the Tablo Hemodialysis System for acute, post-acute, and home dialysis providers.

Next Steps

• The Company plans to file the full text of Ms. Gaeta's Offer Letter as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Key Dates

Recommendation

Keywords

Outset Medical, CFO appointment, financial guidance, SEC filing, 8-K, corporate governance, shareholder meeting, medical technology, dialysis, equity incentive plan, employee stock purchase plan, KPMG